Clinical Trials · NCT03879577
Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- University of Chicago
- Enrollment
- 53
- Start date
- Nov 2019
- Locations
- 1 site, Nigeria
- Primary endpoint
- Number of Participants With Complete Pathologic Response (pCR)